Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | MPO | P05164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP14 | P50281 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120499 | 0.88 | CHRNB2 (0.68) | KDM4EMPOMEN1KMT2ACYP2D6 | |
| SCHEMBL9612263 | 0.86 | HTR2A (0.67) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL15791145 | 0.84 | HTR2A (0.69) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL31415117 | 0.84 | GPR84 (0.72) | HTR2CMTNR1AMTNR1BGPR84HTR2A | |
| SCHEMBL25004737 | 0.84 | MTNR1A (0.64) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL4303662 | 0.83 | KDM4E (0.70) | KDM4EMPOMEN1KMT2ACYP2D6 | |
| Iodide SCHEMBL26662755 | 0.82 | MTNR1A (0.62) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL26662832 | 0.82 | MTNR1A (0.62) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| Iodide SCHEMBL30672189 | 0.82 | MTNR1A (0.62) | MEN1KMT2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL12464834 | 0.82 | HTR2A (0.71) | MPOMEN1KMT2AHTR2CMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| CN-104387382-A | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC | 2015-03-04 | — | — | CN | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878733-A1 | Pyrimidine derivatives as ALK-5 inhibitors | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | KDM4E 445/4885MPO 1308/4885MEN1 2898/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KDM4E 1637/4885MPO 3866/4885MEN1 3074/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KDM4E 1637/4885MPO 3866/4885MEN1 3074/4885 |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | KDM4E 853/4885MPO 3818/4885MEN1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.